Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
6.77
-0.28 (-3.97%)
Dec 20, 2024, 4:00 PM EST - Market closed
Actuate Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
132.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionACTU News
- 4 days ago - Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 7 weeks ago - Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development - GlobeNewsWire
- 3 months ago - Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma - GlobeNewsWire
- 3 months ago - Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline - Seeking Alpha
- 4 months ago - Actuate Therapeutics Announces Closing of Initial Public Offering - GlobeNewsWire
- 4 months ago - Actuate Therapeutics Announces Pricing of Initial Public Offering - GlobeNewsWire
- 5 months ago - U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing - Seeking Alpha